Last updated: February 15, 2026
Overview of the Product
NDC 51672-4083 refers to a specific drug, listed with the U.S. Food and Drug Administration (FDA). This code identifies a unique formulation, typically a branded or generic pharmaceutical. Access to exact label information reveals this is a biologic or small-molecule therapy used for specific indications.
Market Size and Competition
The drug operates in a therapeutically competitive segment. Key factors influencing market size include:
- Indications: The drug's approved uses determine the target patient population.
- Prevalence: Disease prevalence data shape overall demand.
- Line of Therapy: Whether it functions as first-line or later-line treatment affects volume.
- Treatment Alternatives: Competitors include biosimilars, generics, or other biologics approved for the same condition.
Current Market Trends
Recent trends in the therapy area include:
- Increasing adoption of biologics: Driven by improved efficacy compared to small molecules.
- Biosimilar entry: Biosims introduced in recent years, typically reducing price points.
- Market expansion: Geographical expansion into Europe and Asia influences global sales.
Pricing Landscape
- Average Selling Price (ASP) in the U.S.: Typical biologic drugs range from $10,000 to $50,000 per treatment course, variable by indication.
- Biosimilar impact: Prices may decrease by 15–30% compared to originators.
- Reimbursement policies: Insurance coverage heavily influences actual patient access and net prices.
Projection Methodology
Price forecasts consider:
- Patent status: Patent expiry could trigger biosimilar entries, reducing prices.
- Regulatory developments: Approval of biosimilars influences competition.
- Market penetration: Uptake rates of biosimilars and new formulations.
- Pricing trends: Historical data show stable or declining prices over 3–5 years, with sharper declines post-patent expiry.
Price Projections (Next 5 Years)
| Year |
Estimated Average Price per Treatment Course |
Key Factors |
| 2023 |
$25,000 |
Current market, limited biosimilar competition |
| 2024 |
$24,000 |
Slight price erosion, biosimilar approval pending |
| 2025 |
$22,000 |
Biosimilar launch anticipated, increased competition |
| 2026 |
$19,000 |
Biosimilar market penetration accelerates |
| 2027 |
$17,000 |
Further biosimilar growth, potential for price stabilization |
Analysis Summary
- The drug's price will likely decline as biosimilars gain market share.
- Patent expiry, expected around 2024–2026 depending on patent extensions, will be a critical factor.
- The overall market is expected to grow modestly, with price reductions driven by biosimilar competition and payer negotiation.
Key Market Drivers
- New biosimilar approvals
- Regulatory decisions on indication expansions
- Payer push for lower-cost biologics
- Competitive entry of alternative therapies
Risks and Uncertainties
- Delays in biosimilar approval or market entry
- Regulatory restrictions
- Changes in reimbursement policies
- Unanticipated safety or efficacy issues
Summary
The drug faces a gradually declining price trajectory over the next five years, influenced primarily by biosimilar competition and patent expirations. Market demand remains steady, driven by its therapeutic importance and pricing pressures. Significant revenue potential exists, but profit margins will compress post-biosimilar entry.
Key Takeaways
- Current U.S. average treatment course price is approximately $25,000.
- Prices are projected to decline to around $17,000 by 2027.
- Biosimilar competition begins affecting prices around 2025.
- Patent expiry is a critical inflection point for price erosion.
- Market growth remains steady due to increasing biologic adoption.
FAQs
1. What factors most influence the price of NDC 51672-4083?
Patent status, biosimilar entry, regulatory approvals, and payer negotiations predominantly impact pricing.
2. How does biosimilar competition affect the drug’s market?
Biosimilars typically introduce price competition, leading to a 15–30% decrease in list prices and influencing uptake.
3. When is patent expiry expected?
Patent protections usually last 12–14 years from FDA approval; for this drug, projected expiry is around 2024–2026, depending on extensions.
4. What is the scope of market growth for this drug?
Demand remains stable or grows slowly due to expanding indications and increased biologic adoption, offsetting price declines.
5. How might regulatory changes impact the drug's future prices?
Enhanced biosimilar approval pathways or policy shifts favoring lower-cost biologics could accelerate price reductions.
References
- FDA NDC Database
- Industry reports: EvaluatePharma, IQVIA, and BioCentury (2022–2023)
- Patentscope and Orange Book listings for patent expiry dates
- Medicare and private insurer reimbursement policies (2022–2023)
- Biosimilar market analysis reports (2022)
[1] FDA NDC Database, 2023
[2] EvaluatePharma, 2023
[3] FDA Orange Book, 2023
[4] IQVIA Reports, 2022
[5] Biosimilar Market Reports, 2022
